RecruitingPhase 1NCT05018767

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Aging Frailty

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty

Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Enrollment

86 participants

Start Date

Jan 22, 2022

Study Type

INTERVENTIONAL

Conditions

Frailty

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Aging Frailty

Eligibility

Inclusion Criteria2

Diagnosis of Aging Frailty
Understanding and willingness to sign a written informed consent document

Exclusion Criteria10

Active infection
Active cancer
Chronic multisystem organ failure
Pregnancy
Clinically significant abnormalities on pre-treatment laboratory evaluation
Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
Continued drug abuse
Pre-menopausal women not using contraception
Previous organ transplant
Hypersensitivity to sulfur